CIK 0001787306
- Large accelerated filer
Arcutis Biotherapeutics, Inc.
Sign in to watch- Ticker
- ARQT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812974255
- Phone
- +1 805-418-5006
- Business address
- 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361
- Former names
- Arcutis, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,253,826
- in 9 filings, $2.1M under 10b5-1 plans
Net −$3,253,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-02-09 | Watanabe Todd Franklin President and CEO | Exercise or conversion | +1,000 | $1.68 | $2K | 595,779 |
| 2022-02-09 | Watanabe Todd Franklin President and CEO | Sale | −1,000 | $17.00 | $17K | 594,779 |
| 2022-02-09 | Watanabe Todd Franklin President and CEO | Exercise or conversion · Stock Option (Right to Buy) | −1,000 | 119,635 | ||
| 2022-01-05 | Watanabe Todd Franklin President and CEO | Exercise or conversion | +1,000 | $1.68 | $2K | 595,779 |
| 2022-01-05 | Watanabe Todd Franklin President and CEO | Sale | −300 | $22.40 | $7K | 595,479 |
| 2022-01-05 | Watanabe Todd Franklin President and CEO | Sale | −100 | $22.06 | $2K | 595,379 |
| 2022-01-05 | Watanabe Todd Franklin President and CEO | Sale | −600 | $21.11 | $13K | 594,779 |
| 2022-01-05 | Watanabe Todd Franklin President and CEO | Exercise or conversion · Stock Option (Right to Buy) | −1,000 | 120,635 | ||
| 2022-01-03 | Matsuda Masaru SVP and General Counsel | Grant or award · Stock Option (Right to Buy) | +185,000 | 185,000 | ||
| 2022-01-03 | Welgus Howard G. Director | Exercise or conversion | +2,500 | $0.58 | $1K | 184,396 |
| 2022-01-03 | Welgus Howard G. Director | Sale | −2,500 | $21.21 | $53K | 181,896 |
| 2022-01-03 | Welgus Howard G. Director | Exercise or conversion · Stock Option (Right to Buy) | −2,500 | 15,106 | ||
| 2021-12-30 | Burnett Patrick | Grant or award | +16,750 | 26,250 | ||
| 2021-12-30 | Burrows Scott L Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +55,704 | 55,704 | ||
| 2021-12-27 | Burrows Scott L Chief Financial Officer | Sale | −12,560 | $20.07 | $252K | 22,679 |
| 2021-12-23 | Welgus Howard G. Director | Exercise or conversion | +2,500 | $0.58 | $1K | 184,396 |
| 2021-12-23 | Welgus Howard G. Director | Sale | −2,500 | $20.16 | $50K | 181,896 |
| 2021-12-23 | Welgus Howard G. Director | Exercise or conversion · Stock Option (Right to Buy) | −2,500 | 17,606 | ||
| 2021-12-08 | Watanabe Todd Franklin President and CEO | Exercise or conversion | +1,000 | $1.68 | $2K | 595,779 |
| 2021-12-08 | Watanabe Todd Franklin President and CEO | Sale | −1,000 | $17.00 | $17K | 594,779 |
Page 33 of 35 · 689 trades